CiNii 図書 - Nuclear imaging in drug discovery, development, and approval

It is the purpose and business of the pharmaceutical industry to dis- cover, develop, and make available drugs for the care of the sick. The purpose of universities and national laboratories is to provide people and scientific knowledge that can help in the process. This book presents the combined efforts of scientists from the drug in- dustry, academic laboratories and national laboratories to describe advances in radiotracer technology in studies on experimental ani- mals and living human beings. The authors believe that the technol- ogy is now ready for widespread application in the pharmaceutical industry. The goal of this book is to help bring this about. The field of Nuclear Medicine is based on the concept that, if treatment of disease is chemical, the patient's diagnosis should be chemical. Anatomy and histopathology have been the principle ba- sis for making a diagnosis. Histopathologic data suffer from being descriptive, subjective, not quantifiable, and based on the study of dead tissue. The era of histopathology as the dominant concept in medical practice is coming to an end. Histopathologic findings are often heterogeneous and a single biopsy will at times not reveal the true nature of the disease, such as the grading of malignancy. Far greater accuracy of staging of disease and in the planning of treat- ment is possible through chemistry, as well as by making possible a more suitable selection of a histological biopsy site.

1. Nuclear Imaging in Drug Development-Introduction.- 2. Nuclear Medicine Physics, Instrumentation, and Data Processing in Pharmaceutical Research.- 3. Accelerators for Positron Emission Tomography.- 4. Chemistry of Tracers for Positron Emission Tomography.- 5. Single Photon, Gamma Emitting Radiotracers for Use in Imaging.- 6. The Design of Site-Directed Radiopharmaceuticals for Use in Drug Discovery.- 7. Applications of Autoradiography to Drug Discovery.- 8. Quantitative Whole Body Autoradiographic Microimaging for Pharmaceutical Research.- 9. Cerebral Metabolic Rates of 2-[18F]Fluoro-2-Deoxy-D-Glucose in the Presence of Ofloxacin A GABAA Receptor Antagonist.- 10. Positron Emission Tomography, Enzymes and Drug Research and Development.- 11. The Role of Positron Emission Tomography in Assessing and Monitoring Dopamine Active Drugs.- 12. Iodinated Dopamine D1 and D2 Receptor Imaging Agents for SPECT.- 13. Radiolabeled Atrial Natriuretic Peptide and Somatostatin for In Vivo Imaging of Receptors.- 14. Use of Radionuclides in Experimental Vascular Thrombosis.- 15. Application of Nuclear Imaging to Drug Delivery Evaluation and Development: A Review of Radiolabeled, Injectable, Colloidal Systems of Delivery.- 16. The Gastrointestinal Transit and Systemic Absorption of Diltiazem HCL from a Modified Release Dosage Form.- 17. The Potential Uses of Radiopharmaceuticals in the Pharmaceutical Industry.

巻冊次: Berlin ISBN 9783764336011

内容説明

Explores the application of nuclear imaging as a research tool for use by pharmaceutical and biotechnology companies to aid in drug discovery, development and the approval of new pharmaceuticals.

「Nielsen BookData」より

Nuclear imaging in drug discovery, development, and approval

著者

書誌事項

大学図書館所蔵全1件

この図書・雑誌をさがす

注記

内容説明・目次

詳細情報

書き出し